Ocrelizumab/hyaluronidase explained
| Type: | combo |
| Component1: | Ocrelizumab |
| Class1: | Monoclonal antibody |
| Component2: | Hyaluronidase |
| Class2: | Endoglycosidase |
| Tradename: | Ocrevus Zunovo |
| Dailymedid: | Ocrelizumab and hyaluronidase |
| Routes Of Administration: | Subcutaneous |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
Ocrelizumab/hyaluronidase, sold under the brand name Ocrevus Zunovo, is a fixed-dose combination medication used for the treatment of multiple sclerosis. It contains ocrelizumab, a recombinant humanized monoclonal antibody directed at CD20; and hyaluronidase (human recombinant), an endoglycosidase. It is taken by subcutaneous injection.
Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.[2] [3]
Medical uses
Ocrelizumab/hyaluronidase is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease; and primary progressive multiple sclerosis.
Notes and References
- Web site: Ocrevus Zunovo- ocrelizumab and hyaluronidase injection, solution . DailyMed . 25 September 2024 . 5 October 2024.
- FDA Approves Ocrevus Zunovo as the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis . Genentech . 13 September 2024 . 13 September 2024 . 14 September 2024 . https://web.archive.org/web/20240914061044/https://www.gene.com/media/press-releases/15036/2024-09-13/fda-approves-ocrevus-zunovo-as-the-first . live .
- Halozyme Announces FDA Approval of Roche's Subcutaneous Ocrevus Zunovo with Enhanze for People with Relapsing and Primary Progressive Multiple Sclerosis . Halozyme Therapeutics . PR Newswire . 13 September 2024 . 13 September 2024 . 14 September 2024 . https://web.archive.org/web/20240914061013/https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-roches-subcutaneous-ocrevus-zunovo-with-enhanze-for-people-with-relapsing-and-primary-progressive-multiple-sclerosis-302247928.html . live .
